Nicholas Topley

List of Publications by Year
in descending order

		236925	243625
47 papers	4,138 citations	25 h-index	44 g-index
48 all docs	48 docs citations	48 times ranked	4246 citing authors

#	Article	IF	Citations
1	Measurement of innate immune response biomarkers in peritoneal dialysis effluent using aÂrapid diagnostic point-of-care device asÂaÂdiagnostic indicator of peritonitis. Kidney International, 2020, 97, 1253-1259.	5.2	21
2	Peritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis Patients. Frontiers in Physiology, 2019, 10, 105.	2.8	22
3	Identification of clinical and urine biomarkers for uncomplicated urinary tract infection using machine learning algorithms. Scientific Reports, 2019, 9, 19694.	3.3	36
4	Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1526-1533.	4.5	34
5	Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solutionâ€“induced fibrosis. Kidney International, 2018, 94, 346-362.	5.2	28
6	Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes. Kidney International, 2017, 91, 1088-1103.	5.2	53
7	miR-21 Promotes Fibrogenesis in Peritoneal Dialysis. American Journal of Pathology, 2017, 187, 1537-1550.	3.8	30
8	Machine-learning algorithms define pathogen-specific local immune fingerprints inÂperitoneal dialysis patients with bacterial infections. Kidney International, 2017, 92, 179-191.	5.2	56
9	A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent. Kidney International, 2017, 92, 988-1002.	5.2	24
10	IL-6 Transâ€“Signaling Links Inflammation with Angiogenesis in the Peritoneal Membrane. Journal of the American Society of Nephrology: JASN, 2017, 28, 1188-1199.	6.1	67
11	Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysisâ€“Associated Fibrosis. Journal of the American Society of Nephrology: JASN, 2017, 28, 461-478.	6.1	37
12	The Authors Reply. Kidney International, 2017, 92, 1290.	5.2	0
13	Unconventional Human T Cells Accumulate at the Site of Infection in Response to Microbial Ligands and Induce Local Tissue Remodeling. Journal of Immunology, 2016, 197, 2195-2207.	0.8	42
14	ILâ€•10 differentially controls the infiltration of inflammatory macrophages and antigenâ€•presenting cells during inflammation. European Journal of Immunology, 2016, 46, 2222-2232.	2.9	29
15	Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. Nephrology Dialysis Transplantation, 2016, 31, 480-486.	0.7	47
16	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 35-42.	2.3	23
17	FP563MICRORNA REGULATION OF MACROPHAGE PHENOTYPE IN PERITONEAL FIBROSIS. Nephrology Dialysis Transplantation, 2015, 30, iii262-iii262.	0.7	0
18	Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The BAL Anz Trial. Peritoneal Dialysis International, 2015, 35, 159-171.	2.3	7

#	Article	IF	Citations
19	Pathogen-Specific Immune Fingerprints during Acute Infection: The Diagnostic Potential of Human ÃŽÂ³ÃŽÂ´ T-Cells. Frontiers in Immunology, 2014, 5, 572.	4.8	13
20	Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation. Immunity, 2014, 40, 40-50.	14.3	297
21	Pathogen-Specific Local Immune Fingerprints Diagnose Bacterial Infection in Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2013, 24, 2002-2009.	6.1	54
22	Suppression of pro-inflammatory T-cell responses by human mesothelial cells. Nephrology Dialysis Transplantation, 2013, 28, 1743-1750.	0.7	6
23	Independent Effects of Systemic and Peritoneal Inflammation on Peritoneal Dialysis Survival. Journal of the American Society of Nephrology: JASN, 2013, 24, 2071-2080.	6.1	161
24	Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial Î³Î´ T Cell Responses in Early Infection. PLoS Pathogens, 2011, 7, e1002040.	4.7	106
25	The Pathophysiology of the Peritoneal Membrane. Journal of the American Society of Nephrology: JASN, 2010, 21, 1077-1085.	6.1	221
26	A Rapid Crosstalk of Human Î³Î´ T Cells and Monocytes Drives the Acute Inflammation in Bacterial Infections. PLoS Pathogens, 2009, 5, e1000308.	4.7	114
27	How Can Genetic Advances Impact on Experimental Models of Encapsulating Peritoneal Sclerosis?. Peritoneal Dialysis International, 2008, 28, 16-20.	2.3	8
28	Inhibition of Nitric Oxide Synthase Reverses Permeability Changes in a Mouse Model of Acute Peritonitis. Peritoneal Dialysis International, 2005, 25, 11-14.	2.3	16
29	CA125: Holy Grail or a Poisoned Chalice. Nephron Clinical Practice, 2005, 100, c52-c54.	2.3	10
30	Animal models in peritoneal dialysis: more questions than answers?. Peritoneal Dialysis International, 2005, 25, 33-4.	2.3	6
31	Peritoneal dialysis solution biocompatibility testing: a realistic alternative?. Peritoneal Dialysis International, 2005, 25, 348-51.	2.3	2
32	The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney International, 2004, 66, 408-418.	5.2	355
33	A Spoonful of Sugar. Nephron Clinical Practice, 2003, 93, c83-c84.	2.3	0
34	Can Artifact Mimic the Pathology of the Peritoneal Mesothelium?. Peritoneal Dialysis International, 2003, 23, 428-433.	2.3	17
35	Interplay between IFN-Î³ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. Journal of Clinical Investigation, 2003, 112, 598-607.	8.2	229
36	Morphologic Changes in the Peritoneal Membrane of Patients with Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 470-479.	6.1	851

#	Article	IF	Citations
37	Interleukin-6 Levels Decrease in Effluent from Patients Dialyzed with Bicarbonate/Lactateâ€"Based Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2001, 21, 102-107.	2.3	70
38	The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB Journal, 2001, 15, 43-58.	0.5	539
39	Early Peritoneal Responses to Bacterial Invasion: Cellular Exudation. Sepsis, 1999, 3, 303-309.	0.5	1
40	Insulin Stimulates the Activity of Na+/K+-Atpase in Human Peritoneal Mesothelial Cells. Peritoneal Dialysis International, 1997, 17, 186-193.	2.3	11
41	Human peritoneal fibroblast proliferation in 3-dimensional culture: Modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney International, 1997, 51, 205-215.	5.2	73
42	Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney International, 1996, 50, 1212-1223.	5.2	71
43	Peritoneal defence in peritoneal dialysis. Nephrology, 1996, 2, s167-s171.	1.6	4
44	Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1Î² and TNFÎ±. Kidney International, 1993, 43, 226-233.	5.2	238
45	Cell Function and Viability in Glucose Polymer Peritoneal Dialysis Fluids. Peritoneal Dialysis International, 1993, 13, 104-111.	2.3	57
46	Impact of Peritoneal Dialysis Solutions on Peritoneal Immune Defense. Peritoneal Dialysis International, 1993, 13, 291-294.	2.3	33
47	Factors affecting the measurement of chemiluminescence in stimulated human polymorphonuclear leucocytes. Luminescence, 1986, 1, 15-27.	0.0	19